Skip to main content
PMC home page
Biophysical Journal logoLink to Biophysical Journal
. 1998 Aug;75(2):672–682. doi: 10.1016/S0006-3495(98)77557-5

Nature of interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(Carbonyl-bis[imino-N-methyl-4, 2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino] )bis-(1, 3-naphthalene disulfonate).

M Zamai 1, V R Caiolfa 1, D Pines 1, E Pines 1, A H Parola 1
PMCID: PMC1299742  PMID: 9675169

Abstract

PNU145156E (7,7-(carbonyl-bis[imino-N-methyl-4, 2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino]) -bis-(1, 3-naphthalene disulfonate)) is a naphthalene sulfonic distamycin A derivative that interacts with heparin-binding growth factors. Because PNU145156E inhibits tumor angiogenesis, it was selected for clinical development. Picosecond time-resolved fluorescence emission and anisotropy were used to characterize the binding of PNU145156E to the basic fibroblast growth factor (a protein associated with tumor angiogenesis). A decrease in PNU145156E fluorescence lifetime was observed as a function of human basic fibroblast growth factor (bFGF) concentration. Nonlinear least-squares fitting of the binding isotherm yielded Kd = 145 nM for a single class of binding sites. Time-resolved anisotropy gave Kd = 174 nM. Kd = 150 nM was independently verified by quantitative high-performance affinity chromatography. The displaced volume of the complex, calculated from its rotational correlation time, fitted a sphere of 1:1 stoichiometry. These results account for the formation of a tight yet reversible PNU145156E:bFGF complex. An evaluation of PNU145156E fluorescence lifetimes in various solvents has highlighted the forces involved in stabilizing the complex. These are mostly electrostatic-hydrophobic in nature, with a relatively low contribution from hydrogen bonding. Both polar and nonpolar groups are involved on the protein-binding site within a largely hydrophobic cleft. A potential binding trajectory, based on a combination of these results with site-directed chemical modification and known bFGF x-ray structure, is suggested.

Full Text

The Full Text of this article is available as a PDF (223.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alfahel E., Korngreen A., Parola A. H., Priel Z. Purinergically induced membrane fluidization in ciliary cells: characterization and control by calcium and membrane potential. Biophys J. 1996 Feb;70(2):1045–1053. doi: 10.1016/S0006-3495(96)79650-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Auerbach W., Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther. 1994 Sep;63(3):265–311. doi: 10.1016/0163-7258(94)90027-2. [DOI] [PubMed] [Google Scholar]
  3. Aviezer D., Levy E., Safran M., Svahn C., Buddecke E., Schmidt A., David G., Vlodavsky I., Yayon A. Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J Biol Chem. 1994 Jan 7;269(1):114–121. [PubMed] [Google Scholar]
  4. Baird A., Schubert D., Ling N., Guillemin R. Receptor- and heparin-binding domains of basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2324–2328. doi: 10.1073/pnas.85.7.2324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Basilico C., Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res. 1992;59:115–165. doi: 10.1016/s0065-230x(08)60305-x. [DOI] [PubMed] [Google Scholar]
  6. Blood C. H., Zetter B. R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta. 1990 Jun 1;1032(1):89–118. doi: 10.1016/0304-419x(90)90014-r. [DOI] [PubMed] [Google Scholar]
  7. Brent G. A., Moore D. D., Larsen P. R. Thyroid hormone regulation of gene expression. Annu Rev Physiol. 1991;53:17–35. doi: 10.1146/annurev.ph.53.030191.000313. [DOI] [PubMed] [Google Scholar]
  8. Burgess W. H., Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem. 1989;58:575–606. doi: 10.1146/annurev.bi.58.070189.003043. [DOI] [PubMed] [Google Scholar]
  9. Burke T. G., Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem. 1994 Jan 7;37(1):40–46. doi: 10.1021/jm00027a005. [DOI] [PubMed] [Google Scholar]
  10. Caccia P., Nitti G., Cletini O., Pucci P., Ruoppolo M., Bertolero F., Valsasina B., Roletto F., Cristiani C., Cauet G. Stabilization of recombinant human basic fibroblast growth factor by chemical modifications of cysteine residues. Eur J Biochem. 1992 Mar 1;204(2):649–655. doi: 10.1111/j.1432-1033.1992.tb16678.x. [DOI] [PubMed] [Google Scholar]
  11. Ciomei M., Pastori W., Mariani M., Sola F., Grandi M., Mongelli N. New sulfonated distamycin A derivatives with bFGF complexing activity. Biochem Pharmacol. 1994 Jan 20;47(2):295–302. doi: 10.1016/0006-2952(94)90020-5. [DOI] [PubMed] [Google Scholar]
  12. Eriksson A. E., Cousens L. S., Matthews B. W. Refinement of the structure of human basic fibroblast growth factor at 1.6 A resolution and analysis of presumed heparin binding sites by selenate substitution. Protein Sci. 1993 Aug;2(8):1274–1284. doi: 10.1002/pro.5560020810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Faham S., Hileman R. E., Fromm J. R., Linhardt R. J., Rees D. C. Heparin structure and interactions with basic fibroblast growth factor. Science. 1996 Feb 23;271(5252):1116–1120. doi: 10.1126/science.271.5252.1116. [DOI] [PubMed] [Google Scholar]
  14. Fassina G., Chaiken I. M. Analytical high-performance affinity chromatography. Adv Chromatogr. 1987;27:247–297. [PubMed] [Google Scholar]
  15. Fernig D. G., Gallagher J. T. Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor Res. 1994;5(4):353–377. doi: 10.1016/0955-2235(94)00007-8. [DOI] [PubMed] [Google Scholar]
  16. Folkman J., Klagsbrun M. Angiogenic factors. Science. 1987 Jan 23;235(4787):442–447. doi: 10.1126/science.2432664. [DOI] [PubMed] [Google Scholar]
  17. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1985;43:175–203. doi: 10.1016/s0065-230x(08)60946-x. [DOI] [PubMed] [Google Scholar]
  18. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971 Nov 18;285(21):1182–1186. doi: 10.1056/NEJM197111182852108. [DOI] [PubMed] [Google Scholar]
  19. Gullino P. M. Angiogenesis and oncogenesis. J Natl Cancer Inst. 1978 Sep;61(3):639–643. [PubMed] [Google Scholar]
  20. Klagsbrun M., Baird A. A dual receptor system is required for basic fibroblast growth factor activity. Cell. 1991 Oct 18;67(2):229–231. doi: 10.1016/0092-8674(91)90173-v. [DOI] [PubMed] [Google Scholar]
  21. La Rocca R. V., Stein C. A., Myers C. E. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells. 1990 Apr;2(4):106–115. [PubMed] [Google Scholar]
  22. Lindahl U., Lidholt K., Spillmann D., Kjellén L. More to "heparin" than anticoagulation. Thromb Res. 1994 Jul 1;75(1):1–32. doi: 10.1016/0049-3848(94)90136-8. [DOI] [PubMed] [Google Scholar]
  23. Liotta L. A., Steeg P. S., Stetler-Stevenson W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991 Jan 25;64(2):327–336. doi: 10.1016/0092-8674(91)90642-c. [DOI] [PubMed] [Google Scholar]
  24. Middaugh C. R., Mach H., Burke C. J., Volkin D. B., Dabora J. M., Tsai P. K., Bruner M. W., Ryan J. A., Marfia K. E. Nature of the interaction of growth factors with suramin. Biochemistry. 1992 Sep 22;31(37):9016–9024. doi: 10.1021/bi00152a044. [DOI] [PubMed] [Google Scholar]
  25. Myers C., Cooper M., Stein C., LaRocca R., Walther M. M., Weiss G., Choyke P., Dawson N., Steinberg S., Uhrich M. M. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol. 1992 Jun;10(6):881–889. doi: 10.1200/JCO.1992.10.6.881. [DOI] [PubMed] [Google Scholar]
  26. Ornitz D. M., Herr A. B., Nilsson M., Westman J., Svahn C. M., Waksman G. FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. Science. 1995 Apr 21;268(5209):432–436. doi: 10.1126/science.7536345. [DOI] [PubMed] [Google Scholar]
  27. Ornitz D. M., Yayon A., Flanagan J. G., Svahn C. M., Levi E., Leder P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol. 1992 Jan;12(1):240–247. doi: 10.1128/mcb.12.1.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sola F., Farao M., Pesenti E., Marsiglio A., Mongelli N., Grandi M. Antitumor activity of FCE 26644 a new growth-factor complexing molecule. Cancer Chemother Pharmacol. 1995;36(3):217–222. doi: 10.1007/BF00685849. [DOI] [PubMed] [Google Scholar]
  29. Springer B. A., Pantoliano M. W., Barbera F. A., Gunyuzlu P. L., Thompson L. D., Herblin W. F., Rosenfeld S. A., Book G. W. Identification and concerted function of two receptor binding surfaces on basic fibroblast growth factor required for mitogenesis. J Biol Chem. 1994 Oct 28;269(43):26879–26884. [PubMed] [Google Scholar]
  30. Thompson L. D., Pantoliano M. W., Springer B. A. Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry. 1994 Apr 5;33(13):3831–3840. doi: 10.1021/bi00179a006. [DOI] [PubMed] [Google Scholar]
  31. Vlodavsky I., Bar-Shavit R., Ishai-Michaeli R., Bashkin P., Fuks Z. Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem Sci. 1991 Jul;16(7):268–271. doi: 10.1016/0968-0004(91)90102-2. [DOI] [PubMed] [Google Scholar]
  32. Yayon A., Klagsbrun M., Esko J. D., Leder P., Ornitz D. M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 1991 Feb 22;64(4):841–848. doi: 10.1016/0092-8674(91)90512-w. [DOI] [PubMed] [Google Scholar]
  33. Zhu H., Ramnarayan K., Anchin J., Miao W. Y., Sereno A., Millman L., Zheng J., Balaji V. N., Wolff M. E. Glu-96 of basic fibroblast growth factor is essential for high affinity receptor binding. Identification by structure-based site-directed mutagenesis. J Biol Chem. 1995 Sep 15;270(37):21869–21874. doi: 10.1074/jbc.270.37.21869. [DOI] [PubMed] [Google Scholar]
  34. Zhu X., Komiya H., Chirino A., Faham S., Fox G. M., Arakawa T., Hsu B. T., Rees D. C. Three-dimensional structures of acidic and basic fibroblast growth factors. Science. 1991 Jan 4;251(4989):90–93. doi: 10.1126/science.1702556. [DOI] [PubMed] [Google Scholar]

Articles from Biophysical Journal are provided here courtesy of The Biophysical Society

RESOURCES